Medical Condition News

RSS

Reducing levels of SUN1 protein increases life span of mice with progeria, heart disease

Scientists have discovered that they can dramatically increase the life span of mice with progeria (premature ageing disease) and heart disease (caused by Emery-Dreifuss muscular dystrophy) by reducing levels of a protein called SUN1.

30 Apr 2012

Antibody that neutralizes enzyme Kallikrein 6 staves off MS

Researchers studying multiple sclerosis(MS) have long been looking for the specific molecules in the body that cause lesions in myelin, the fatty, insulating cells that sheathe the nerves.

30 Apr 2012

Protein vital for cell survival and immune balance has another form with different function

Research led by St. Jude Children's Research Hospital investigators suggests that safeguarding cell survival and maintaining a balanced immune system is just the start of the myeloid cell leukemia sequence 1 (MCL1) protein's work.

30 Apr 2012

AlderMed enters distribution agreement with Gulmay Medical for Xstrahl-100 therapy system

AlderMed announced today it has entered into a three-year exclusive distribution agreement with Gulmay Medical, manufacturer of the Xstrahl-100 therapy system.

From Xstrahl 30 Apr 2012

Teens with high levels of uric acid at increased risk for high blood pressure

Teens with high levels of uric acid appear to be at increased risk for high blood pressure, according to results of research from scientists at the Johns Hopkins Children's Center.

30 Apr 2012

Human iPS cells accrue genetic changes at about the same rate as replicating cells

A team of researchers from Johns Hopkins University and the National Human Genome Research Institute has evaluated the whole genomic sequence of stem cells derived from human bone marrow cells—so-called induced pluripotent stem (iPS) cells—and found that relatively few genetic changes occur during stem cell conversion by an improved method.

30 Apr 2012

Kadimastem, Merck Serono enter agreement for MS drug-screening platform

Kadimastem, an Israeli Biotechnology company that develops human pluripotent stem cell-related products, today announced the signing of a five year framework agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

30 Apr 2012

Rexahn obtains additional patent coverage for anti-cancer candidate RX-1792 in Japan

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued to the Company patent No. 4,934,432, entitled "Quinazoline Derivatives and Therapeutic Use Thereof."

30 Apr 2012

JCO publishes Syndax erlotinib-entinostat Phase 2 study for advanced non-small cell lung cancer

Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO).

30 Apr 2012

Astounding lack of public awareness about lung cancer

An astounding lack of public awareness about lung cancer has been revealed in a Cancer Research UK study, published today.

30 Apr 2012

Potential hazards of performing MRI in patients with cardiac pacemaker

Great care should be taken when performing magnetic resonance imaging (MRI) in patients with a cardiac pacemaker. Henning Bovenschulte and his co-authors review recent findings in the latest issue of Deutsches Ärzteblatt International.

30 Apr 2012

Teva, Mylan settle patent infringement litigation for Nuvigil

Teva Pharmaceutical Industries Ltd., one of the world's largest producers of pharmaceuticals, announces that it has settled patent infringement litigation regarding U.S. Patent Number 7,132,570 (the "'570 patent") with respect to Mylan Inc.'s ANDA for Teva's wakefulness product NUVIGIL (armodafinil) tablets.

30 Apr 2012

BTG launches Voraxaze for treatment of toxic plasma methotrexate

BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.

30 Apr 2012

Enrollment complete in Zalicus Synavive Phase 2b clinical trial for rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced it has completed enrollment with 292 patients enrolled in the SYNERGY trial, a Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).

30 Apr 2012

New class of drugs hold promise against aggressive forms of pancreatic cancer

Cancer Research UK-funded scientists have shown how a promising new class of drugs might be used to treat aggressive forms of pancreatic cancer, according to a study published in Nature.

30 Apr 2012

Tolero granted exclusive global rights to commercialize MannKind's novel BTK compounds

Tolero Pharmaceuticals and MannKind Corporation today announced a license agreement granting Tolero exclusive worldwide rights to develop and commercialize compounds from MannKind's novel BTK (Bruton's tyrosine kinase) program, which are currently being developed for the treatment of hematological malignancies and inflammatory diseases.

30 Apr 2012

Scientists discover number of unknown brain networks linked with teen drug abuse

Why do some teenagers start smoking or experimenting with drugs-while others don't? In the largest imaging study of the human brain ever conducted-involving 1,896 14-year-olds-scientists have discovered a number of previously unknown networks that go a long way toward an answer.

30 Apr 2012

Mount Sinai experts to share skin cancer prevention tips on May 7

Skin cancer is the most common form of cancer in the United States, with one in five Americans developing it over the course of their lives. It's also one of the most preventable types of cancers. Since May is Skin Cancer Awareness Month and Melanoma Monday is May 7, Mount Sinai experts are sharing tips on prevention and insight on the new FDA labeling requirements on sunscreen.

30 Apr 2012

Parents underestimate their daughters' reproductive concerns

Researchers at Moffitt Cancer Center and colleagues have found that adolescents newly diagnosed with cancer have strong concerns about their ability to have children as cancer survivors. They also found that standard health-related quality-of-life survey tools used to elicit answers from teens with cancer did not accurately reflect these concerns. Parents, who often answer survey questions as proxies, often inaccurately relayed their child's reproductive concerns.

30 Apr 2012

MCC researchers aim to improve cancer patient's quality of life and care

Researchers at Moffitt Cancer Center have placed new emphasis on gathering data on cancer patient quality of life during both treatment and survivorship. Their focus is on gathering and using that data to develop interventions to improve the quality of life for patients in treatment and for cancer survivors.

30 Apr 2012

Medical Condition News

Reducing levels of SUN1 protein increases life span of mice with progeria, heart disease

Antibody that neutralizes enzyme Kallikrein 6 staves off MS

Protein vital for cell survival and immune balance has another form with different function

AlderMed enters distribution agreement with Gulmay Medical for Xstrahl-100 therapy system

Teens with high levels of uric acid at increased risk for high blood pressure

Human iPS cells accrue genetic changes at about the same rate as replicating cells

Kadimastem, Merck Serono enter agreement for MS drug-screening platform

Rexahn obtains additional patent coverage for anti-cancer candidate RX-1792 in Japan

JCO publishes Syndax erlotinib-entinostat Phase 2 study for advanced non-small cell lung cancer

Astounding lack of public awareness about lung cancer

Potential hazards of performing MRI in patients with cardiac pacemaker

Teva, Mylan settle patent infringement litigation for Nuvigil

BTG launches Voraxaze for treatment of toxic plasma methotrexate

Enrollment complete in Zalicus Synavive Phase 2b clinical trial for rheumatoid arthritis

New class of drugs hold promise against aggressive forms of pancreatic cancer

Tolero granted exclusive global rights to commercialize MannKind's novel BTK compounds

Scientists discover number of unknown brain networks linked with teen drug abuse

Mount Sinai experts to share skin cancer prevention tips on May 7

Parents underestimate their daughters' reproductive concerns

MCC researchers aim to improve cancer patient's quality of life and care

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News